{"denoms":[{"counts":[{"groupId":"BG000","value":"20"}],"units":"Participants"}],"groups":[{"description":"Trabectedin 1.5 mg/m2 IV over 24 hours every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"BG000","title":"Trabectidin"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"<40 years"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"40-49 years"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"50-59 years"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"60-69 years"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"70-79 years"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":">79 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Eligible and treated patients"}